Norgine B.V. has sold the Canadian assets of its subsidiary Merus Labs International Inc. to Searchlight Pharma Inc., a Montreal based specialty pharmaceutical company controlled by Fonds de solidarité FTQ and Emerillon Capital. Financial terms were not disclosed
Searchlight will take ownership of and assume the distribution and promotion of Enablex® and Vancocin® in Canada effective immediately. Norgine acquired Merus Labs International Inc. in July 2017 for $342 million. Norgine will retain all assets in markets outside Canada. photo credit: Searchlight Pharam
News Release
Norgine B.V. to divest its Canadian assets acquired through Merus Labs International Inc. to Searchlight Pharma
Norgine acquired Merus Labs International Inc. in July 2017 and will retain all assets outside Canada
Searchlight Pharma takes ownership of and assumes distribution of Enablex® and Vancocin® in Canada effective immediately
Norgine’s Canadian assets generated approximately €3.4 million (CAD $5.1 million) in sales in 2017
AMSTERDAM and MONTREAL, Oct. 1, 2018 /CNW Telbec/ – Norgine B.V. (“Norgine”) and Searchlight Pharma Inc. (“Searchlight”) are pleased to announce the closing of a transaction whereby Searchlight will acquire the Canadian assets of Norgine’s subsidiary Merus Labs International Inc. (“Merus”). As a result of the transaction, Searchlight will take ownership of and assume the distribution and promotion of Enablex® and Vancocin® in Canada effective immediately. Norgine will retain all assets in markets outside Canada. Financial terms of the transaction were not disclosed. According to IQVIA CDH data, the Merus business in Canada generated €3.4 million (CAD $5.1 million) in sales during the 12 month period ending December 2017. Merus’ Canadian product portfolio consists of Enablex® (darifenacin) which is an anti-muscarinic prescription drug indicated for the treatment of overactive bladder and Vancocin® (vancomycin) which is a prescription antibiotic indicated for the treatment of various infections. Peter Stein, CEO of Norgine said: “The divestment of Norgine’s Canadian assets, acquired as part of the Merus acquisition, ensures that patients in the region will continue to benefit from Enablex® and Vancocin®. This will enable Norgine to drive our European strategy to deliver profitable growth and create a dynamic and sustainable business in the long term. Norgine will use the proceeds of this transaction to acquire further specialist products for sale through our European infrastructure.”
“The acquisition of Enablex® and Vancocin® is further evidence of the success of our industry-leading business development activities,” said Mark Nawacki, President & CEO of Searchlight Pharma. “The opportunity to acquire the Canadian Merus business represented a unique chance to strategically build both commercial scale and our product offering. Enablex®, in particular, fits well with our growing interest and presence in the specialty urology and urogynaecology markets in Canada, and will complement our existing promotional activities in support of Bulkamid® for the treatment of stress urinary incontinence. With Enablex® and Bulkamid® in our portfolio we can now offer a synergistic offering of prescription solutions that address the spectrum of urinary incontinence issues affecting Canadian patients.”
Notes to editors
About Enablex®
Enablex® (darifenacin) is indicated for the treatment of overactive bladder. Overactive bladder is used to describe a collection of urinary symptoms composed of urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of proven infection or other obvious pathology. Enablex® belongs to a class of medicines called antimuscarinic medicines, which reduces abnormal bladder contractions, and is formulated as a once-a-day extended release tablet for oral use containing 7.5 mg or 15 mg of darifenacin. About Vancocin®
Vancocin® (vancomycin) is indicated for the treatment of infections caused by susceptible strains of staphylococcal enterocolitis, and antibiotic-associated pseudomembranous colitis produced by Clostridium difficile. Vancomycin is in a class of medications called glycopeptide antibiotics, and is formulated as gelatin capsules containing 125 mg or 250 mg vancomycin. About Norgine
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net product sales were EUR 345 million, up 17 per cent. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply. Norgine specialises in gastroenterology, hepatology, cancer and supportive care. Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France. For more information, please visit www.norgine.com. In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com. NORGINE and the sail logo are trademarks of the Norgine group of companies. About Searchlight Pharma
Searchlight Pharma Inc., headquartered in Montreal, aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women’s health, urology, and pediatrics, our team is committed to improving people’s lives by bringing the right products to market. Follow us, learn more about what we do, and get to know our product portfolio at www.searchlightpharma.com. SOURCE Searchlight Pharma Inc.
For further information: for media representatives only: Isabelle Jouin, Corporate Communications, Norgine, T: +44 (0)1895 453643; Mark Nawacki, CPA, CA, President & CEO Searchlight Pharma Inc., Phone: 514-613-1513, info@searchlightpharma.com; For other queries: Christopher Bath, CFO, Norgine, T: +44(0)1895 453723
Related Posts

PE-backed Searchlight Pharma acquires Merus Labs’ Canadian Assets from Norgine

.
Publicado 01/10/2018 14:02:20 CET
ÁMSTERDAM y MONTREAL, October 1, 2018 /PRNewswire/ --
-- Norgine B.V. desinvierte sus activos canadienses adquiridos por medio de Merus Labs International Inc. para Searchlight Pharma  
- Norgine adquirió Merus Labs International Inc. en julio de 2017, y mantendrá todos           los activos fuera de Canadá           - Searchlight Pharma toma la propiedad y asume la distribución de Enablex(R)            y Vancocin(R) en Canadá con efecto inmediato           - Los activos de Norgine en Canadá han generado unos 3,4 millones de euros (5,1 millones           de dólares canadienses) en ventas en el año 2017
Norgine B.V. ("Norgine") y Searchlight Pharma Inc. ("Searchlight") se complacen al anunciar el cierre de la transacción mediante el cual Searchlight adquirirá los activos de Canadá de la filial de Norgine, Merus Labs International Inc. ("Merus"). Como resultado de la transacción, Searchlight tomará la propiedad de ella, asumiendo la distribución y promoción de Enablex(R) y Vancocin(R) en Canadá con efecto inmediato. Norgine mantendrá todos sus activos en mercados de fuera de Canadá. No se han desvelado los términos financieros de la transacción. Según los datos de IQVIA CDH, los negocios de Merus en Canadá han generado 3,4 millones de euros (5,1 millones de dólares canadienses) en ventas en el periodo de 12 meses que finalizó en diciembre de 2017. La cartera de productos canadienses de Merus está formada por Enablex(R) (darifenacina), que es un fármaco por prescripción anti-muscarínico indicado para el tratamiento de la vejiga con exceso de actividad y Vancocin(R)  (vancomicina), que es un antibiótico por prescripción indicado para el tratamiento de varias infecciones. Peter Stein, consejero delegado de Norgine, destacó: "La desinversión de los activos canadienses de Norgine, adquiridos como parte de la adquisición de Merus, asegura que los pacientes de la región seguirán beneficiándose de Enablex(R) y Vancocin[(R)]. Esto permitirá a Norgine impulsar nuestra estrategia de Europa para desplegar un crecimiento beneficioso y crear unos negocios dinámicos y sostenibles a largo plazo. Norgine utilizará los beneficios de esta transacción para adquirir más productos especialistas para su venta por medio de nuestra estructura de Europa". "La adquisición de Enablex(R) y Vancocin(R) es una evidencia superior del éxito de nuestras actividades de desarrollo de negocios líderes en la industria", destacó Mark Nawacki, director general y consejero delegado de Searchlight Pharma. "La oportunidad para adquirir los negocios de Canadian Merus ha representado una oportunidad única de construir estratégicamente la oferta de productos y la escala comercial. Enablex(R), en particular, encaja a la perfección con nuestros intereses crecientes y presencia en los mercados especializados de urología y urologinecología de Canadá, y complementará nuestras actividades promocionales existentes en apoyo a Bulkamid(R) para el tratamiento de la incontinencia por estrés urinario. Con Enablex(R) y Bulkamid(R) en nuestra cartera, podemos proporcionar una oferta de sinergia de soluciones por prescripción que se dirigen a un espectro de incontinencias urinarias que afectan a los pacientes de Canadá". Información solo para representantes de medios:             Isabelle Jouin          Comunicaciones empresariales de Norgine          Teléfono: +44-(0)-1895-453-643           Mark Nawacki, CPA, CA          Director general y consejero delegado de Searchlight Pharma Inc.          Teléfono: 514-613-1513          info@searchlightpharma.com
Vea el comunicado multimedia en  http://www.norgine.com/media
Photo:      http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg
+34 91 359 26 00
+34 91 359 26 00

COMUNICADO: Norgine B.V. desinvierte sus activos canadienses adquiridos por medio de Merus Labs International Inc.

Share this article
Norgine acquired Merus Labs International Inc. in July 2017 and will retain all assets outside Canada
Searchlight Pharma takes ownership of and assumes distribution of Enablex® and Vancocin® in Canada effective immediately
Norgine's Canadian assets generated approximately €3.4 million (CAD $5.1 million) in sales in 2017
AMSTERDAM and MONTREAL, Oct. 1, 2018 /CNW Telbec/ - Norgine B.V. ("Norgine") and Searchlight Pharma Inc. ("Searchlight") are pleased to announce the closing of a transaction whereby Searchlight will acquire the Canadian assets of Norgine's subsidiary Merus Labs International Inc. ("Merus"). As a result of the transaction, Searchlight will take ownership of and assume the distribution and promotion of Enablex® and Vancocin® in Canada effective immediately. Norgine will retain all assets in markets outside Canada. Financial terms of the transaction were not disclosed. According to IQVIA CDH data, the Merus business in Canada generated €3.4 million (CAD $5.1 million) in sales during the 12 month period ending December 2017. Merus' Canadian product portfolio consists of Enablex® (darifenacin) which is an anti-muscarinic prescription drug indicated for the treatment of overactive bladder and Vancocin® (vancomycin) which is a prescription antibiotic indicated for the treatment of various infections. Peter Stein, CEO of Norgine said: "The divestment of Norgine's Canadian assets, acquired as part of the Merus acquisition, ensures that patients in the region will continue to benefit from Enablex® and Vancocin®. This will enable Norgine to drive our European strategy to deliver profitable growth and create a dynamic and sustainable business in the long term. Norgine will use the proceeds of this transaction to acquire further specialist products for sale through our European infrastructure." "The acquisition of Enablex® and Vancocin® is further evidence of the success of our industry-leading business development activities," said Mark Nawacki, President & CEO of Searchlight Pharma. "The opportunity to acquire the Canadian Merus business represented a unique chance to strategically build both commercial scale and our product offering. Enablex®, in particular, fits well with our growing interest and presence in the specialty urology and urogynaecology markets in Canada, and will complement our existing promotional activities in support of Bulkamid® for the treatment of stress urinary incontinence. With Enablex® and Bulkamid® in our portfolio we can now offer a synergistic offering of prescription solutions that address the spectrum of urinary incontinence issues affecting Canadian patients." Notes to editors
About Enablex®
Enablex® (darifenacin) is indicated for the treatment of overactive bladder. Overactive bladder is used to describe a collection of urinary symptoms composed of urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of proven infection or other obvious pathology. Enablex® belongs to a class of medicines called antimuscarinic medicines, which reduces abnormal bladder contractions, and is formulated as a once-a-day extended release tablet for oral use containing 7.5 mg or 15 mg of darifenacin. About Vancocin®
Vancocin® (vancomycin) is indicated for the treatment of infections caused by susceptible strains of staphylococcal enterocolitis, and antibiotic-associated pseudomembranous colitis produced by Clostridium difficile. Vancomycin is in a class of medications called glycopeptide antibiotics, and is formulated as gelatin capsules containing 125 mg or 250 mg vancomycin. About Norgine
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine's total net product sales were EUR 345 million, up 17 per cent. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply. Norgine specialises in gastroenterology, hepatology, cancer and supportive care. Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France. For more information, please visit www.norgine.com . In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit  www.norgineventures.com . NORGINE and the sail logo are trademarks of the Norgine group of companies. About Searchlight Pharma
Searchlight Pharma Inc., headquartered in Montreal, aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women's health, urology, and pediatrics, our team is committed to improving people's lives by bringing the right products to market. Follow us, learn more about what we do, and get to know our product portfolio at www.searchlightpharma.com . SOURCE Searchlight Pharma Inc.
For further information:  for media representatives only: Isabelle Jouin, Corporate Communications, Norgine, T: +44 (0)1895 453643; Mark Nawacki, CPA, CA, President & CEO Searchlight Pharma Inc., Phone: 514-613-1513, info@searchlightpharma.com; For other queries: Christopher Bath, CFO, Norgine, T: +44(0)1895 453723
Related Links

Norgine B.V. to divest its Canadian assets acquired through Merus Labs International Inc. to Searchlight Pharma
								  								  
  		
	
				
								
							Français

AMSTERDAM et MONTRÉAL, October 1, 2018 /PRNewswire/ --
Norgine a acquis Merus Labs International Inc. en juillet 2017 et conservera tous les actifs se trouvant à l'extérieur du Canada
Pharmaceutique Searchlight acquiert la propriété et assume la distribution d'Enablex[MD] et de Vancocin[MD] au Canada avec prise d'effet immédiate
Les actifs canadiens de Norgine ont généré des ventes d'environ 3,4 millions € (5,1 millions $ CA) en 2017
Norgine B.V. (« Norgine ») et Pharmaceutique Searchlight Inc. (« Searchlight ») sont heureuses d'annoncer la clôture d'une transaction aux termes de laquelle Searchlight acquerra les actifs canadiens de Merus Labs International Inc. (« Merus »), une filiale de Norgine. Par suite de cette transaction, Searchlight acquerra la propriété et assumera la distribution et la promotion d'Enablex[MD] et de Vancocin[MD] au Canada avec prise d'effet immédiate. Norgine conservera les actifs dans les marchés autres que le Canada. Les modalités financières de la transaction n'ont pas été communiquées. Selon les données CDH d'IQVIA, les activités de Merus au Canada ont généré des ventes de 3,4 millions € (5,1 millions $ CA) pour la période de 12 mois terminée en décembre 2017. Le portefeuille canadien de produits de Merus comprend Enablex[MD] (darifenacin), un médicament antimuscarinique sur ordonnance indiqué pour le traitement de la vessie hyperactive, et Vancocin[MD] (vancomycine), un antibiotique sur ordonnance indiqué pour le traitement de diverses infections. « La cession des actifs canadiens de Norgine, acquis dans le cadre de l'acquisition de Merus, assure que les patients de la région continueront de bénéficier d'Enablex[MD] et de Vancocin[MD], a déclaré Peter Stein, chef de la direction de Norgine. Elle permettra à Norgine de faire avancer notre stratégie européenne consistant à générer une croissance rentable et à créer une entreprise dynamique et durable à long terme. Norgine utilisera le produit de cette transaction pour acquérir d'autres produits spécialisés en vue de la vente par l'entremise de notre infrastructure européenne. »
« L'acquisition d'Enablex[MD] et de Vancocin[MD] témoigne encore une fois du succès de nos activités de développement des affaires de premier plan dans l'industrie, a indiqué Mark Nawacki, président-directeur général de Pharmaceutique Searchlight. L'opportunité d'acquérir les activités canadiennes de Merus a constitué une chance unique d'élargir de façon stratégique notre envergure commerciale et notre offre de produits. L'Enablex[MD], en particulier, cadre bien avec notre intérêt et présence en croissance dans les marchés spécialisés de l'urologie et de l'urogynécologie du Canada, et complètera les activités promotionnelles que nous exerçons actuellement pour soutenir le Bulkamid[MD] pour le traitement de l'incontinence urinaire d'effort. Avec Enablex[MD] et Bulkamid[MD] au sein de notre portefeuille, nous pouvons maintenant proposer une offre synergique de solutions sur ordonnance couvrant l'ensemble des problèmes d'incontinence urinaire touchant les patients canadiens. »
Pour les media

Norgine B.V. cédera ses actifs canadiens acquis par l'entremise de Merus Labs International Inc. à...

ÁMSTERDAM y MONTREAL, October 1, 2018 /PRNewswire/ --
- Norgine B.V. desinvierte sus activos canadienses adquiridos por medio de Merus Labs International Inc. para Searchlight Pharma  
Norgine adquirió Merus Labs International Inc. en julio de 2017, y mantendrá todos los activos fuera de Canadá  
Searchlight Pharma toma la propiedad y asume la distribución de Enablex® y Vancocin® en Canadá con efecto inmediato  
Los activos de Norgine en Canadá han generado unos 3,4 millones de euros (5,1 millones de dólares canadienses) en ventas en el año 2017
Norgine B.V. ("Norgine") y Searchlight Pharma Inc. ("Searchlight") se complacen al anunciar el cierre de la transacción mediante el cual Searchlight adquirirá los activos de Canadá de la filial de Norgine, Merus Labs International Inc. ("Merus"). Como resultado de la transacción, Searchlight tomará la propiedad de ella, asumiendo la distribución y promoción de Enablex® y Vancocin® en Canadá con efecto inmediato. Norgine mantendrá todos sus activos en mercados de fuera de Canadá. No se han desvelado los términos financieros de la transacción. Según los datos de IQVIA CDH, los negocios de Merus en Canadá han generado 3,4 millones de euros (5,1 millones de dólares canadienses) en ventas en el periodo de 12 meses que finalizó en diciembre de 2017. La cartera de productos canadienses de Merus está formada por Enablex® (darifenacina), que es un fármaco por prescripción anti-muscarínico indicado para el tratamiento de la vejiga con exceso de actividad y Vancocin® (vancomicina), que es un antibiótico por prescripción indicado para el tratamiento de varias infecciones. Peter Stein, consejero delegado de Norgine, destacó: "La desinversión de los activos canadienses de Norgine, adquiridos como parte de la adquisición de Merus, asegura que los pacientes de la región seguirán beneficiándose de Enablex® y Vancocin[®]. Esto permitirá a Norgine impulsar nuestra estrategia de Europa para desplegar un crecimiento beneficioso y crear unos negocios dinámicos y sostenibles a largo plazo. Norgine utilizará los beneficios de esta transacción para adquirir más productos especialistas para su venta por medio de nuestra estructura de Europa". "La adquisición de Enablex® y Vancocin® es una evidencia superior del éxito de nuestras actividades de desarrollo de negocios líderes en la industria", destacó Mark Nawacki, director general y consejero delegado de Searchlight Pharma. "La oportunidad para adquirir los negocios de Canadian Merus ha representado una oportunidad única de construir estratégicamente la oferta de productos y la escala comercial. Enablex®, en particular, encaja a la perfección con nuestros intereses crecientes y presencia en los mercados especializados de urología y urologinecología de Canadá, y complementará nuestras actividades promocionales existentes en apoyo a Bulkamid® para el tratamiento de la incontinencia por estrés urinario. Con Enablex® y Bulkamid® en nuestra cartera, podemos proporcionar una oferta de sinergia de soluciones por prescripción que se dirigen a un espectro de incontinencias urinarias que afectan a los pacientes de Canadá". Información solo para representantes de medios:   
Isabelle Jouin

Norgine B.V. desinvierte sus activos canadienses adquiridos por medio de Merus Labs International...

POA Pharma is a pharmaceutical and healthcare company whose areas of competence include gastroenterology, head and neck, and metabolic diseases. On January 8th, 2020, POA Pharma was acquired by Galen. Terms of the transaction were not disclosed.

POA Pharma

Toronto/Gothenburg , January 17 , 2013 -- Merus Labs : MSL ,  : MSLI -RSB- is pleased to announce that through its wholly owned subsidiaries , Merus Labs and Merus Labs , it has entered into promotion and distribution agreements with POA for the Merus Labs ® / Enablex ® product .

POA PHARMA SCANDINAVIA SIGNS DISTRIBUTION AGREEMENT FOR NORTHERN EUROPE WITH MERUS LABS – Poa Pharma

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Startups focused on providing products and services catering to women's health and wellbeing.

Women's Health & Wellness

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Cancer

Acquired

Merus Labs is a specialty pharmaceutical company with products for oncology, women's health, cardiovascular diseases, urology, and infectious diseases.

Wells Fargo Success Story

Professional Services

Platform Overview

Merus Labs

Compete with Merus Labs?

Compete with Merus Labs?

Discover the right solution for your team